Current Procedural Terminology 2010 American Medical Association. All Rights Reserved. Note: Codes published herein are current on the publication/effective date and are subject to change.

Sent To: CAP except Dentists and Pharmacies Contains Public Information

March 7, 2011 S-2-11

The Blue Shield Report is

published by the professional relations department of Blue

Cross and Blue Shield of Kansas.

OUR WEB ADDRESS: http://www.bcbsks.com

Ann Dunn Communications Coordinator

Questions: Contact your professional relations representative or the professional relations hotline in Topeka at 785-291-4135 or 1-800-432-3587.

Acknowledgement: Current Procedural Terminology (CPT®) is copyright 2010 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in CPT®. The AMA assumes no liability for the data contained herein. Applicable ARS/DFARS Restrictions Apply to Government Use.

Inside This Issue: Reminders Changes are Coming . . . ...................................................... Page 2

Updates Ankle Brace & CAM Walker Coding .................................. Page 2 Blepharoplasty ..................................................................... Page 6 Foot Care Guidelines ........................................................... Page 4 Leinwetter Named Medical Director at BCBSKS ............... Page 3 Measurement of High-Sensitivity C-Reactive Protein ........ Page 3 OPPORTUNITY IS KNOCKING!...................................... Page 6 Rapid Influenza Virus Diagnostic Testing & Treatment in the

Outpatient Setting ................................................................ Page 4 Secondary Adjustment Processing for CMS Claims .......... Page 2 Soft Contact Lenses ............................................................. Page 3 Web Changes – Medical Review ......................................... Page 5

Pharmaceuticals Biologic Immunomodulators Step Therapy – Through Preferred Agent (Humira) .................................................... Page 8 Direct Renin Inhibitors (DRIs) Added to Antihypertensive

Step Therapy/Prior Authorization Program ......................... Page 7 Formulary Update ................................................................ Page 7

TRICARE TRICARE Provider Seminar Registration ........................... Page 8

Workshop Opportunities EDI Workshops for 2011 ...................................................... Page 10 SAVE THE DATE ............................................................. Page 11

March 7, 2011 Blue Shield Report S-2-11 Page 2

Current Procedural Terminology 2010 American Medical Association. All Rights Reserved.

Note: Codes published herein are current on the publication/effective date and are subject to change. Sent To: CAP except Dentists and Pharmacies

Contains Public Information

Reminders

Changes are Coming . . .

. . . to the Health Care Reform (HCR) section of the Blue Cross and Blue Shield of Kansas (BCBSKS) Web site. You will be among the first to know of these changes if you are signed up to receive the HCR eNewsletter. You may sign up by clicking on the link to the left to get that newsletter to be notified when significant changes are made to the site. As soon as all enhancements are in production, the eNewsletter will outline the changes in detail.

Please note: This eNewsletter is ONLY for Health Care Reform; it is in addition to the Professional Relations notifications regarding the Blue Shield Report and publication updates.

Updates

Secondary Adjustment Processing for CMS Claims BCBSKS is aware of CMS corrections to the 2010 Medicare Physician Fee Schedule (MPFS) which were implemented with a retroactive effective date of Friday, January 1, 2010. We understand that claims processed by Medicare between January 1 through June 30, 2010 will be mass adjusted to reflect the revised fee schedule. These adjustments are automatically being crossed over from the Medicare Coordination of Benefits Contractor (COBC) to BCBSKS for secondary adjustment processing. Due to the large workload, BCBSKS is taking steps to ensure that retroactive secondary adjusted claims coming from Medicare are processed timely and accurately. We expect that this reprocessing effort will take some time and will vary depending upon the claim-type and volume. Please do NOT re-file your crossover claims. No action is required from the BCBSKS provider. Ankle Brace & CAM Walker Coding

The correct code to use for a prefabricated lace-up ankle brace is HCPCS Code L1902: "Ankle-foot orthotic (AFO), ankle gauntlet, prefabricated, includes fitting and adjustment." The correct code to use for a custom fabricated ankle brace where a mold of the ankle-foot is taken is HCPCS L1904: "Ankle-foot orthotic (AFO), molded ankle gauntlet, custom fabricated.” Also, another reminder: the correct HCPCS code to be used for a CAM Walker is L4360, “Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated, includes fitting and adjustment.”

March 7, 2011 Blue Shield Report S-2-11 Page 3

Current Procedural Terminology 2010 American Medical Association. All Rights Reserved.

Note: Codes published herein are current on the publication/effective date and are subject to change. Sent To: CAP except Dentists and Pharmacies

Contains Public Information

Leinwetter Named Medical Director at Blue Cross and Blue Shield of Kansas Myron Leinwetter, D.O., has joined Blue Cross and Blue Shield of Kansas as the company's medical director of quality improvement, cost containment and medical policy. Dr. Leinwetter is responsible for directing quality improvement activities such as provider peer review and preventive services activities. He also is responsible for leading activities relating to cost containment initiatives, directing the URAC accreditation process and compliance, and serving as a medical resource for medical review, precertification, case management and care management. He previously served as medical director of the Shawnee County Health Agency, where he helped expand the agency’s physical plant locations, recruited additional medical staff, and directed the implementation of an electronic medical records system. He also has 13 years experience with the Cotton-O’Neil medical group and five years at a satellite clinic in Montezuma. In addition, Dr. Leinwetter has done missionary work in Costa Rica.

Dr. Leinwetter earned his pharmacy degree from the University of Kansas School of Pharmacy, and his medical degree from the University of Health Sciences-College of Osteopathic Medicine in Kansas City. He is a member of the Shawnee County Medical Society, and is the current president of the Kansas State Board of Healing Arts. Dr. Leinwetter and his wife, Tandy, live in Rossville. Measurement of High-Sensitivity C-Reactive Protein C-reactive protein (CRP) is an acute phase reactant that has long been used to monitor inflammatory processes, such as infection and autoimmune diseases. Recent studies have suggested that low-level chronic inflammation may play a role in atherogenesis, and thus measurement of CRP has been investigated in various settings of cardiovascular disease. Measurement of high-sensitivity C-reactive protein is considered experimental/investigational as a method of cardiac risk stratification. Appropriate coding for the use of high-sensitivity C-reactive protein is CPT code 86141. Appropriate coding for the use of standard C-reactive protein for monitoring inflammatory processes is CPT code 86140. This medical policy is currently in effect. Soft Contact Lenses Soft contact lenses are not allowed for diagnosis of keratoconus. They are non covered since the soft contact lens used for this diagnosis is really to improve vision, not to alter the progression of the disease.

March 7, 2011 Blue Shield Report S-2-11 Page 4

Current Procedural Terminology 2010 American Medical Association. All Rights Reserved.

Note: Codes published herein are current on the publication/effective date and are subject to change. Sent To: CAP except Dentists and Pharmacies

Contains Public Information

Foot Care Guidelines Routine foot care is a non-covered service. Routine foot care includes any foot care service performed in the absence of localized illness, injury, or symptoms, involving the foot. These services include cutting or removal of corns and calluses; clipping or trimming of normal or mycotic nails; shaving, paring, cutting or removal of keratoma, tyloma, and heloma; non-definitive simple, palliative treatments like shaving or paring of plantar warts which do not require thermal or chemical cautery and curettage; and other hygienic and preventive maintenance care in the realm of self-care, such as cleaning and soaking the feet and the use of skin creams to maintain skin tone of both ambulatory and bedridden patients. Exceptions to this exclusion apply to systemic conditions such as metabolic, neurologic, or peripheral vascular disease resulting in medically significant circulatory deficits or decreased sensation to the foot, such that the performance of routine foot care by a nonprofessional person may pose a hazard. Foot care services will be covered for these systemic conditions when billed with the following CPT codes: 11055: Paring or cutting of benign hyperkeratotic lesion (eg, corn or callus); single lesion 11056: Paring or cutting of benign hyperkeratotic lesion (eg, corn or callus); 2 to 4 lesions 11057: Paring or cutting of benign hyperkeratotic lesion (eg, corn or callus); more than 4 lesions G0247: Routine foot care by a physician of a diabetic patient with diabetic sensory neuropathy

resulting in a loss of protective sensation (LOPS) to include the local care of superficial wounds (i.e., superficial to muscle and fascia) and at least the following, if present: (1) local care of superficial wounds, (2) debridement of corns and calluses, and (3) trimming and debridement of nails

S0390: Routine foot care; removal and/or trimming of corns, calluses and/or nails and preventive maintenance in specific medical conditions (e.g., diabetes), per visit

This policy becomes effective 30 days from the date of this newsletter. Rapid Influenza Virus Diagnostic Testing & Treatment in the Outpatient Setting

Most patients with a clinical illness consistent with uncomplicated influenza, who reside in an area where influenza virus are circulating, do not require diagnostic influenza testing for clinical management, including antiviral treatment decisions. When testing is appropriate, CPT code 87804 should be used. The following are guidelines regarding diagnostic influenza testing: 1. The clinical presentation of patients with uncomplicated influenza virus infection includes: abrupt onset of fever, cough, sore throat, myalgias, arthralgias, chills, headache, and fatigue.

2. Most patients with a clinical illness consistent with uncomplicated influenza, who reside in an area

where influenza virus are circulating, do not require diagnostic influenza testing for clinical management, including antiviral treatment decisions.

3. Rapid influenza diagnostic tests have limited sensitivity and false negative results are common.

Thus, negative results from rapid influenza diagnostic tests should not be used to guide decisions regarding treatment with influenza antiviral medications. In addition, false positive tests can occur

March 7, 2011 Blue Shield Report S-2-11 Page 5

Current Procedural Terminology 2010 American Medical Association. All Rights Reserved.

Note: Codes published herein are current on the publication/effective date and are subject to change. Sent To: CAP except Dentists and Pharmacies

Contains Public Information

Rapid Influenza Virus Diagnostic Testing & Treatment in the Outpatient Setting, continued

and are more likely when influenza is rare in the community. When laboratory confirmation is desired, testing by RT-PCR and/or viral culture is recommended. If most circulating influenza viruses have similar antiviral susceptibilities, information on influenza A subtypes may not be needed to inform clinical care.

4. Persons at high risk of influenza complications include: progressive, severe, or complicated illness, regardless of previous health status, people age 65 years and older, young children, pregnant women, people with long term health conditions such as asthma, diabetes, neurologic and neurodevelopmental disorders, heart disease, and people with immunosuppressive conditions or medications.

5. The medical necessity of influenza virus testing and treatment will be based on CDC recommendations: http://www.cdc.gov/h1n1flu/guidance/diagnostic_tests.htm

Web Changes – Medical Policy

Since the publication of Blue Shield Report S-7-10, the following new or revised medical policies have been posted to our Web site at: http://www.bcbsks.com/CustomerService/Providers/MedicalPolicies/policies.htm

• Ambulatory Event Monitors and Mobile Outpatient Cardiac Telemetry • Ampyra (dalfampridine) Prior Authorization (with Quantity Limit) Criteria (new policy) • Balloon Sinuplasty for Treatment of Chronic Sinusitis • Barrett’s Esophagus Treatments (Maintenance) • Botulinum Toxin (BT) • Bronchial Thermoplasty (new policy) • Computed Tomographic Angiography (CTA) and Magnetic Resonance Angiography (MRA) of the Head, Neck,

Abdomen, Pelvis, and Extremities • Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pseudomyxoma Peritonei and

Peritoneal Carcinomatosis of Gastrointestinal Origin • Diagnosis and Medical Management of Obstructive Sleep Apnea Syndrome (formerly known as Polysomnography

and Sleep Studies) • Fundus Photography • Hyperbaric Oxygen Pressurization (HBO2) • Implanted Peripheral Nerve Stimulator (PNS) for Pain Control • Intravenous and Subcutaneous Immune Globulin Therapy • Measurement of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) in the Assessment of Cardiovascular Risk • Monitored and General Anesthesia Services • Novel Lipid Risk Factors in Risk Assessment and Management of Cardiovascular Disease • Oral Oncology Agents Prior Authorization Criteria (new policy) • Periureteral Bulking Agents as a Treatment of Vesicoureteral Reflux (VUR) • Radiofrequency Ablation of Miscellaneous Solid Tumors Excluding Liver Tumors (new policy) • Scanning Computerized Ophthalmic Diagnostic Imaging Devices • Scintimammography/Breast-Specific Gamma Imaging/Molecular Breast Imaging (new policy) • Small Bowel/Liver and Multivisceral Transplant • Stereotactic Radiosurgery and Radiotherapy • Testing for Vitamin D Deficiency • Total Body Plethysmography

• Vagus Nerve Stimulation

A complete listing of all medical policies can be found on our Web site at http://www.bcbsks.com/CustomerService/Providers/MedicalPolicies/policies.htm

March 7, 2011 Blue Shield Report S-2-11 Page 6

Current Procedural Terminology 2010 American Medical Association. All Rights Reserved.

Note: Codes published herein are current on the publication/effective date and are subject to change. Sent To: CAP except Dentists and Pharmacies

Contains Public Information

OPPORTUNITY IS KNOCKING! Is your Blue Shield Report getting lost or bogged down somewhere en route to your office? Do you wish you could have had that information when it was released instead of a week or more after the published date? We are receiving some great responses from provider offices who have signed up for list serve notification via e-mail! One administrator is excited because instead of routing or copying the Blue Shield Report newsletters, all stakeholders may subscribe to receive the newsletters and notices of updates at their desktops. Another states, "I, along with all appropriate personnel, receive the newsletter as soon as it is released, and we receive notification of medical policy revisions the week they are posted."

The benefits are clear: timely receipt of written communications with direct links to identified documents from your BCBSKS Provider Relations department, administrative efficiency, word search capability, and a summary of information available through the attached link. To sign up for the Professional Relations Mailing List, visit us on the Web at www.bcbsks.com and select "Customer Service for Providers." Below the green box in the upper left corner is a link to "e-News." Select the bullet for "Professional Providers." Or, you may click here to register now. Once the process is completed, you will receive an e-mail to which you must respond to complete the subscription. NOTE: Subscribing to the mail list will stop all paper copies of the newsletter to your office. Be sure to have everyone in the office sign up for e-mail notification if they wish to receive e-mails of Professional Relations newsletters. Don't miss out on critical information! Sign up for e-News today!

Blepharoplasty The following are the documentation requirements for Blepharoplasty—plastic surgery of the upper eyelids. Providers must submit all of the following requirements when submitting a claim or predetermination.

1. Documentation of symptoms

2. Visual Fields—Visual Fields must be recorded. Each eye should be tested with the upper eyelid at rest and repeated with the lid elevated to demonstrate an expected surgical improvement meeting or exceeding the criteria (minimum of 12 degrees or 30% loss of upper field of vision.)

3. Photographs—Prints (do not submit slides) must be frontal, canthus-to-canthus (side-view) with

the head perpendicular to the plane of the camera (not tilted) to demonstrate a skin rash or position of the true lid margin or the pseudo-lid margin. The photos must be of sufficient clarity to show a light reflex on the cornea. If redundant skin coexists with true lid ptosis, additional photos must be taken with the upper lid skin retracted to show the actual position of the true lid

March 7, 2011 Blue Shield Report S-2-11 Page 7

Current Procedural Terminology 2010 American Medical Association. All Rights Reserved.

Note: Codes published herein are current on the publication/effective date and are subject to change. Sent To: CAP except Dentists and Pharmacies

Contains Public Information

Blepharoplasty, continued

margin (needed if both 15822 and 15823 are required and planned in addition to 67900-67908). Oblique photos are only needed to demonstrate redundant skin on the upper eyelashes when this is the only indication for surgery.

4. Operative report when filing a claim.

Note: If both a blepharoplasty and a brow ptosis repair are planned, medical necessity for both must be individually documented. This may require two sets of photographs showing the effect of drooping of redundant skin (and its correction by taping) and the actual presence of blepharoptosis.

Pharmaceuticals

Formulary Update

Prime Therapeutics updates the BCBSKS formulary (preferred drug list) on a quarterly basis. Please refer to the link below when prescribing or dispensing medications for your Blue Cross and Blue Shield of Kansas patients. Coverage is subject to the limitations of the member's individual plan.

• http://www.bcbsks.com/CustomerService/PrescriptionDrugs/pdf/2377KS_NatSelectPhysicianFmlryBklt.pdf

A searchable version of the formulary is available at:

• https://www.myprime.com/MyRx/MyPrime/Commercial/findDrugs/KSBCBS/SAMST#ViewFindDrugsEvent

Direct Renin Inhibitors (DRIs) Added to Antihypertensive Step Therapy/Prior Authorization Program DRIs and combination antihypertensive products containing DRIs will be added to the antihypertensive step therapy/prior authorization program. These drugs include Amturnide (aliskiren/amlodipine/HCTZ), Tekamlo (aliskiren/amlodipine), Tekturna (aliskiren), Tekturna HCT (aliskiren/HCTZ), Valturna (aliskiren/valsartan). A complete list of brand and generic drugs impacted by the Antihypertensive Step Therapy/Prior Authorization Program is available at the following link:

http://www.bcbsks.com/CustomerService/PrescriptionDrugs/priorauth_HighBloodPressure.htm These programs require a member to initially use an available generic alternative drug such as an angiotensin converting enzyme inhibitor (ACEI) or angiotensin-II receptor blocker (ARB) prior to coverage for brand-name ACEIs, ARBs or DRIs or their combination products. Members currently receiving brand-name therapy may continue to do so without interruption. These programs will only affect new members or members who receive these medications for the first time. An electronic claims edit will determine if a patient has been receiving the brand-name medication or has tried a required generic. In either case, the requested brand-name drug will be approved. Persons new to BCBSKS prescription drug coverage will not have a claim history to automatically approve the brand-name drug. Therefore, a prior authorization (PA) process is in place to provide a manual review of claims that do not meet the electronic edit. The PA form is available at the following link:

http://www.bcbsks.com/CustomerService/Forms/pdf/PriorAuth_ACEI.pdf.

March 7, 2011 Blue Shield Report S-2-11 Page 8

Current Procedural Terminology 2010 American Medical Association. All Rights Reserved.

Note: Codes published herein are current on the publication/effective date and are subject to change. Sent To: CAP except Dentists and Pharmacies

Contains Public Information

Biologic Immunomodulators Step Therapy – Through Preferred Agent (Humira)

The intent of the Biologic Immunomodulators Step Therapy (ST) program is to ensure that patients prescribed therapy are properly selected according to Food and Drug Administration (FDA)-approved product labeling and/or clinical guidelines and/or clinical trials. The criteria encourages the use of first-line conventional agents, some of which are available as generics (for example, first-line agents for arthritis indications, methotrexate and leflunomide, are both available as generics). Criteria also encourage use of a preferred biologic immunomodulator – Humira (adalimumab) before the nonpreferred

agents. Nonpreferred agents include Amevive (alefacept), Cimzia (certolizumab), Enbrel (etanercept), Kineret (anakinra) and Simponi (golimumab). Criteria requires prior treatment with a conventional agent AND the preferred agent Humira (adalimumab) - before use of a nonpreferred biologic immunomodulator. Patients who are stabilized on an existing therapy will be allowed to continue without interruption. An electronic claim edit will identify members who are currently on therapy or who have a history of treatment with a conventional agent and/or the preferred biologic agent, and will allow claims for these members. If there are no claims identified to meet the step therapy requirements, a prior authorization will be required. The BCBSKS medical policy for biologic immunomodulators and prior authorization request form are available at www.bcbsks.com.

TRICARE

TRICARE Provider Seminar Registration TriWest Healthcare Alliance Corp. (TriWest) is offering our latest TRICARE provider education seminars for 2011 throughout the 21-state TRICARE West Region. The seminars in Kansas begin May 3 and run through June 1, and will furnish you and your staff with the latest information on TRICARE programs, policies and procedures. For those new to TRICARE, these seminars are a great opportunity to learn about the TRICARE program. They can also serve as a good refresher for those who have previously attended a TRICARE seminar. If you have recently attended a seminar and feel comfortable with the TRICARE program, you may wish to send another team member from your office or bring a less experienced person with you. Each attendee will receive the newest Provider Handbook and Quick Reference Guides. Updates on the latest enhanced functionality of the secure provider portal will also be covered. Seminars are scheduled for both medical/surgical and behavioral health providers. There is no charge to attend a seminar. Registering online at www.triwest.com/provider is the most convenient way for you to pre-register for a seminar. You will benefit from the following:

• Immediate e-mail confirmation of your registration • Reminder e-mail notice prior to your scheduled seminar • Eligibility to participate in a drawing for a small prize at the seminar

If you have questions regarding the content of provider seminars, you may contact your local TRICARE representative, Joyce White, at (800) 432-3587 (option 4) or (785) 291-4135 (option 4), or e-mail pseminar@triwest.com.

March 7, 2011 Blue Shield Report S-2-11 Page 9

Current Procedural Terminology 2010 American Medical Association. All Rights Reserved.

Note: Codes published herein are current on the publication/effective date and are subject to change. Sent To: CAP except Dentists and Pharmacies

Contains Public Information

TRICARE Provider Seminar Registration, continued Registration is required. By registering online, you will receive an e-mail confirmation and a reminder notice prior to your scheduled seminar. Bring your e-mail confirmation to enter a drawing for a small prize. If you do not have Internet access, you may fax your registration to (866) 867-7925. Please register at least one week prior to the seminar. If you have questions about registration, need to change your registration, or wish to have six or more people from your practice or facility attend, please e-mail pseminar@triwest.com. Please check www.triwest.com/provider prior to attending the seminar to verify location. Check out the table on the following page to locate the seminar most convenient for you. The seminar will run approximately 2½ hours; however, the end time may vary based on the level of audience participation.

TYPE DATE TIME LOCATION CITY Medical/Surgical May 03, 2011 9:00 AM–11:30 AM Riverfront Community Center

123 S Esplanade Room: Riverview

Leavenworth

Medical/Surgical May 04, 2011 9:00 AM–11:30 AM Capitol Plaza Hotel 1717 SW Topeka Blvd Room: Pioneer Room

Topeka

Medical/Surgical May 05, 2011 9:00 AM–11:30 AM Ramada Hotel & Conf Center 1616 W Crawford St Room: Meeting Room C

Salina

Behavioral Health May 18, 2011 1:00 PM–3:30 PM Clarion Hotel-Manhattan 530 Richards Dr Room: Regency B1`

Manhattan

Medical/Surgical May 19, 2011 9:00 AM–11:30 AM Clarion Hotel-Manhattan 530 Richards Dr Room: Regency B1`

Manhattan

Behavioral Health May 24, 2011 1:00 PM–3:30 PM DoubleTree Hotel 10100 College Blvd Room: Seattle II

Overland Park

Medical/Surgical May 25, 2011 9:00 AM–11:30 AM DoubleTree Hotel 10100 College Blvd Room: Seattle I & II

Overland Park

Medical/Surgical May 31, 2011 1:00 PM–3:30 PM Wichita Marriott 9100 Corporate Hills Dr Room: Salons A-E

Wichita

Behavioral Health June 01, 2011 9:00 AM–11:30 AM Wichita Marriott 9100 Corporate Hills Dr Room: Salons A-E

Wichita

March 7, 2011 Blue Shield Report S-2-11 Page 10

Current Procedural Terminology 2010 American Medical Association. All Rights Reserved.

Note: Codes published herein are current on the publication/effective date and are subject to change. Sent To: CAP except Dentists and Pharmacies

Contains Public Information

Workshop Opportunities

EDI Workshops for 2011 EDI Workshops will be held throughout the Kansas and Kansas City area during 2011. With the implementation of 5010, the 2011 EDI workshops will be focused on these changes, as well as changes that will be coming in the near future. A few of the topics to be covered include:

• Migrating to 5010 • 277 CA (Claim Acknowledgement) • Unique Health Plan Identifier • ICD-10

Immediately following the workshop, EDI staff will conduct the “Advanced Options” training for PC-ACE Pro32 software users. Seating will be limited in most locations so early enrollment is recommended. Each provider group is requested to limit registration to two attendees. Registration begins at 8:30 A.M., with the workshop running from 9:00 A.M. to Noon. You may register for any of the workshops listed by clicking on the following link: http://www.bcbsks.com/CustomerService/Providers/EDI/event_listings/workshops.htm DATE CITY LOCATION May 11 Wichita Wesley Medical Center, Cessna Room June 8 Garden City St. Catherine Hospital, Classroom A June 9 Hays Ft. Hays State University, Memorial Union July 13 Chanute Neosho Memorial Regional Medical Center July 14 Kansas City, MO St. Joseph Medical Center July 26 Topeka BCBSKS, Polk School Gym September 27 North Kansas City North Kansas City Hospital, Lewis & Clark Room October 5 Wichita Via Christi – St. Joseph, North end of Cafeteria

March 7, 2011 Blue Shield Report S-2-11 Page 11

Current Procedural Terminology 2010 American Medical Association. All Rights Reserved.

Note: Codes published herein are current on the publication/effective date and are subject to change. Sent To: CAP except Dentists and Pharmacies

Contains Public Information

SAVE THE DATE!